
    
      All 24 subjects will receive either JHL1922 or Pulmozyme as single doses of 2.5 mg and then
      10 mg per eRapid nebulizer, followed after a washout by a 5-period of daily dosing of 10 mg
      of either JHL1922 or Pulmozyme per eRapid nebulizer.

      The primary objective is to assess the similarity of safety and tolerability of test
      products, and the exploratory objective is to assess the similarity, if possible, of the
      systemic levels and sputum levels of dornase alfa after administration of test products.
    
  